Chemistry:DSP-2230

From HandWiki
Short description: Investigational analgesic drug
DSP-2230
DSP-2230.svg
Clinical data
Routes of
administration
By mouth
Identifiers
CAS Number
UNII
ChEMBL
Chemical and physical data
FormulaC20H20F3N5O2
Molar mass419.408 g·mol−1
3D model (JSmol)

DSP-2230 is a selective small-molecule Nav1.7 and Nav1.8 voltage-gated sodium channel blocker which is under development by Dainippon Sumitomo Pharma for the treatment of neuropathic pain.[1][2] As of June 2014, it is in phase I/phase II clinical trials.[1][2]

See also

References

  1. 1.0 1.1 Martz, Lauren (2014). "Nav-i-gating antibodies for pain". Science-Business EXchange 7 (23): 662. doi:10.1038/scibx.2014.662. ISSN 1945-3477. 
  2. 2.0 2.1 "Recent progress in sodium channel modulators for pain". Bioorganic & Medicinal Chemistry Letters 24 (16): 3690–9. August 2014. doi:10.1016/j.bmcl.2014.06.038. PMID 25060923. 

External links